SNS-032 NEW
| Price | $43 | $61 | $88 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: SNS-032 | CAS No.: 345627-80-7 |
| Purity: 99.44% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | SNS-032 |
| Description | SNS-032 (BMS-387032) is a selective inhibitor of CDK2 (IC50: 48 nM), exhibiting 10- and 20-fold selectivity over CDK1 and CDK4, respectively. It is also sensitive to CDK7 (IC50: 62 nM) and CDK9 (IC50: 4 nM), with no effect on CDK6. |
| Cell Research | Cell Titer-Glo (CTG) luminescent assay is performed to measure the growth curves of both HUVECs and U87 mg cells. U87 mg cells and HUVECs (2×103 cells/well) are seeded in a 96-well microplate in a final volume of 100 ml. After 24 hours, cells are treated with various doses of SNS-032 (0–0.5 mM) for 24, 48, or 72 hours. After completion of the treatment, 100 ml of CTG solution is added to each well and incubated for 20 minutes at room temperature in the dark. Lysate (50 ml) is transferred to a 96-well white plate, and luminescence is measured by POLARstar OPTIMA. Percent cell growth is calculated by considering 100% growth at the time of SNS-032 addition.(Only for Reference) |
| In vitro | SNS-032 demonstrates low sensitivity towards CDK1 and CDK4, with IC50 values of 480 nM and 925 nM, respectively. It effectively eradicates chronic lymphocytic leukemia cells in vitro, showing significant effectiveness regardless of prognostic indicators or previous treatments. In comparison to flavopiridol and roscovitine, SNS-032 exhibits superior potency, both in inhibiting RNA synthesis and inducing apoptosis. Its reversibility is notable, as the withdrawal of SNS-032 leads to the reactivation of RNA polymerase II, resynthesis of Mcl-1, and consequently, cell survival. Moreover, SNS-032 inhibits the formation of three-dimensional capillary networks in endothelial cells, completely halting U87 mg cell-mediated capillary formation in HUVECs and significantly reducing VEGF production in both cell lines, thereby preventing in vitro angiogenesis primarily by blocking VEGF. Preclinical studies reveal SNS-032's ability to induce cell cycle arrest and apoptosis in multiple cell lines by inhibiting CDKs 2, 7, and 9, highlighting its effectiveness regardless of human serum presence. It also triggers a dose-dependent increase in annexin V staining and caspase-3 activation, dephosphorylates serine 2 and 5 of RNA polymerase II, and reduces the expression of CDK2 and CDK9, alongside dephosphorylated CDK7. |
| In vivo | SNS-032 prevents tumor cell-induced VEGF secretion in a tumor coculture model. [2] SNS-032, a new CDK inhibitor, is more selective and less cytotoxic and has been shown to prolong stable disease in solid tumors. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 16.67 mg/mL (43.8 mM), Sonication is recommended. |
| Keywords | Cyclin dependent kinase | inhibit | SNS 032 | Inhibitor | CDK | BMS387032 | Apoptosis | BMS 387032 | SNS-032 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1MG |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-03-28 | |
| $0.00/1mg |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-08-26 | |
| $3100.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.01/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-07 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY